Tetanus
Conditions
Keywords
Tetanus Prophylaxis
Brief summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Interventions
DRUGSiltartoxatug Injection (Brand name: Sintetol®)
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Sponsors
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury; * 2\. Provided signed informed consent by themselves or their legal representatives.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome | within 90 days | Tetanus protection rate within 90 days post-administration of Siltartoxatug Injection (calculated as 1- tetanus incidence rate) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Outcome | within 90 days | Classification of wound characteristics in patients receiving Siltartoxatug Injection |
Countries
China
Contacts
Primary ContactXia Qu, Master
Backup Contactxinyu Liu, Doctor
Outcome results
None listed